published meta-analysis   sensitivity analysis   studies

Immunosuppressants drugs in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsCAN-COVID, 2020 0.67 [0.30; 1.50] 0.67[0.30; 1.50]CAN-COVID, 202010%445NAnot evaluable deathsdetailed resultsCAN-COVID, 2020 0.67 [0.30; 1.50] LIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21] SAVE-MORE, 2021 0.45 [0.20; 0.99] 0.62[0.42; 0.92]CAN-COVID, 2020, LIVE-AIR (Temesgen), 2021, SAVE-MORE, 202130%1,518moderatenot evaluable deaths (time to event analysis only)detailed resultsLIVE-AIR (Temesgen), 2021 0.70 [0.40; 1.21] 0.70[0.40; 1.21]LIVE-AIR (Temesgen), 202110%479NAnot evaluable clinical deteriorationdetailed resultsSAVE-MORE, 2021 0.36 [0.26; 0.50] 0.36[0.26; 0.50]SAVE-MORE, 202110%NAnot evaluable clinical improvementdetailed resultsCAN-COVID, 2020 1.39 [0.76; 2.54] 1.39[0.76; 2.54]CAN-COVID, 202010%446NAnot evaluable death or ventilationdetailed resultsLIVE-AIR (Temesgen), 2021 0.65 [0.43; 0.98] 0.65[0.43; 0.98]LIVE-AIR (Temesgen), 202110%NAnot evaluable mechanical ventilationdetailed resultsSAVE-MORE, 2021 0.47 [0.03; 7.48] 0.47[0.03; 7.48]SAVE-MORE, 202110%594NAnot evaluable serious adverse eventsdetailed resultsCAN-COVID, 2020 0.73 [0.45; 1.19] 0.73[0.45; 1.19]CAN-COVID, 202010%448NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-04-29 00:54 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526 - roots T: 290